Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 85/100

Termination Rate

20.0%

1 terminated out of 5 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

4Total
Not Applicable (2)
P 2 (2)

Trial Status

Recruiting3
Active Not Recruiting1
Terminated1

Clinical Trials (5)

Showing 5 of 5 trials
NCT07855757Not ApplicableActive Not Recruiting

Retlirafusp Alfa Plus SOX and Intraperitoneal Nab-Paclitaxel for Advanced Gastric/GEJ Cancer With Malignant Ascites

NCT07133490Phase 2RecruitingPrimary

INTERACT Stomach-II

NCT07556640Phase 2Recruiting

LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study

NCT07313579Recruiting

Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer

NCT03349827Not ApplicableTerminatedPrimary

HIPEC and Systemic Chemotherapy Combined With Apatinib in Unresectable Peritoneal Metastases From Gastric Cancer

Showing all 5 trials

Research Network

Activity Timeline